慢性淋巴细胞白血病中TLR9表达鉴定促迁移亚群及新治疗靶点
本研究探讨TLR9在慢性淋巴细胞白血病(CLL)中的作用。CLL患者血浆游离DNA显著高于健康对照(P < .0001),且与预后标志物相关;TLR9表达与CLL细胞体外迁移相关(P < .001),TLR9激动剂通过NF-κB和STAT3促进迁移。双靶向TLR9和BTK显示强协同作用(中位组合指数0.2),提示联合治疗潜力。
要点
- CLL患者血浆游离DNA升高且与不良预后相关。
- TLR9表达促进CLL细胞迁移,与表面TLR9强相关。
- 双靶向TLR9和BTK具有强协同作用。
核心结论
- TLR9信号在CLL中促进细胞迁移和疾病进展,双靶向TLR9和BTK是潜在更有效治疗策略。
研究设计与样本
- 研究比较CLL患者与健康对照血浆游离DNA水平,分析TLR9表达与迁移关系,并进行RNA测序和小鼠异种移植模型实验。
主要发现
- CLL患者血浆未甲基化DNA显著高于健康对照(P < .0001),游离DNA水平与CD38、β2微球蛋白和淋巴细胞倍增时间相关。
- 游离DNA升高与较短首次治疗时间相关(风险比4.0;P = .003)。
- TLR9表达与体外CLL细胞迁移相关(P < .001),细胞内内体TLR9与表面表达强相关(r = 0.9)。
- 淋巴结来源CLL细胞表面TLR9增高(P = .016),sTLR9hi细胞中TLR信号、黏附、运动和炎症相关基因转录差异。
- TLR9激动剂ODN2006通过p65 NF-κB和STAT3激活促进CLL细胞迁移(P < .001),自体外周血血浆诱导相同效应且可被TLR9拮抗剂逆转。
临床怎么用
- TLR9表达和血浆游离DNA水平可能作为CLL预后评估指标。
- 双靶向TLR9和BTK或为CLL联合治疗新策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic lymphocytic leukemia (CLL) remains incurable despite B-cell receptor-targeted inhibitors revolutionizing treatment. This suggests that other signaling molecules are involved in disease escape mechanisms and resistance. Toll-like receptor 9 (TLR9) is a promising candidate that is activated by unmethylated cytosine guanine dinucleotide-DNA. Here, we show that plasma from patients with CLL contains significantly more unmethylated DNA than plasma from healthy control subjects (P < .0001) and that cell-free DNA levels correlate with the prognostic markers CD38, β2-microglobulin, and lymphocyte doubling time. Furthermore, elevated cell-free DNA was associated with shorter time to first treatment (hazard ratio, 4.0; P = .003). We also show that TLR9 expression was associated with in vitro CLL cell migration (P < .001), and intracellular endosomal TLR9 strongly correlated with aberrant surface expression (sTLR9; r = 0.9). In addition, lymph node-derived CLL cells exhibited increased sTLR9 (P = .016), and RNA-sequencing of paired sTLR9hi and sTLR9lo CLL cells revealed differential transcription of genes involved in TLR signaling, adhesion, motility, and inflammation in sTLR9hi cells. Mechanistically, a TLR9 agonist, ODN2006, promoted CLL cell migration (P < .001) that was mediated by p65 NF-κB and STAT3 transcription factor activation. Importantly, autologous plasma induced the same effects, which were reversed by a TLR9 antagonist. Furthermore, high TLR9 expression promoted engraftment and rapid disease progression in a NOD/Shi-scid/IL-2Rγnull mouse xenograft model. Finally, we showed that dual targeting of TLR9 and Bruton's tyrosine kinase (BTK) was strongly synergistic (median combination index, 0.2 at half maximal effective dose), which highlights the distinct role for TLR9 signaling in CLL and the potential for combined targeting of TLR9 and BTK as a more effective treatment strategy in this incurable disease.
引用
- Kennedy E, Coulter E, Halliwell E, et al. TLR9 expression in chronic lymphocytic leukemia identifies a promigratory subpopulation and novel therapeutic target. Blood. 2021. PMID: 33512408. doi:10.1182/blood.2020005964
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。